Elixir Names Praecis COO William Heiden President And CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
The ex-Schering-Plough exec most recently served as president and COO of Praecis. Elixir's previous CEO resigned to facilitate the firm's transition into a drug development company with a focus on near-term commercial opportunities.
You may also be interested in...
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles
Sepracor Lunesta Ads Are Top At Brand Recognition, IAG Research Finds
Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research